STOCK TITAN
  1. Home
  2. Sec-filings
  3. ORKA
  4. [144] Oruka Therapeutics, Inc. SEC Filing

Oruka officer plans $463K stock sale via options

Oruka Therapeutics, Inc. (ORKA) has a notice of proposed sale of securities filed under Rule 144 by officer Laura Sandler.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) has a notice of proposed sale of securities filed under Rule 144 by officer Laura Sandler. The notice covers the planned resale of 5,000 shares of common stock on or after 09/01/2026 on NASDAQ, to be delivered through exercise of stock options for cash. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker.

The filing also lists prior sales of Oruka common stock for Sandler during the past three months, including 5,000 shares sold on 07/01/2026 and 600 shares sold on 06/15/2026.

Positive

  • None.

Negative

  • None.
Shares of common stock to be sold 5,000 shares Planned Rule 144 sale on or after 09/01/2026
Approximate value of shares to be sold $463,100.00 Value listed for 5,000 common shares associated with 09/01/2026 entry
Shares sold on 07/01/2026 5,000 shares Past three months sales section for Laura Sandler
Proceeds from 07/01/2026 sale $472,078.50 Sale of 5,000 common shares on 07/01/2026
Shares sold on 06/15/2026 600 shares Past three months sales section for Laura Sandler
Proceeds from 06/15/2026 sale $41,814.00 Sale of 600 common shares on 06/15/2026
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
10b5-1 regulatory
"10b5-1 Sales for LAURA SANDLER 855 Oak Grove Avenue Suite 100"
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
Exercise of Stock Options financial
"Common | 09/01/2026 | Exercise of Stock Options | Issuer"
Form 144 regulatory
"144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

What does the Form 144 filing disclose for ORKA?
It discloses that officer Laura Sandler has filed a Rule 144 notice to sell up to 5,000 shares of Oruka Therapeutics, Inc. common stock, to be issued from an exercise of stock options for cash and sold on or after 09/01/2026 on NASDAQ.

How many ORKA shares are planned to be sold under this Form 144?
The notice covers a proposed sale of 5,000 shares of Oruka Therapeutics, Inc. common stock, to be delivered through the exercise of stock options and sold on or after 09/01/2026.

What is the approximate value of the ORKA shares covered by the planned sale?
The Form 144 lists an approximate value of $463,100.00 for the 5,000 shares of Oruka Therapeutics, Inc. common stock covered by the planned Rule 144 sale as of the 09/01/2026 entry.

Which broker is handling the proposed ORKA share sale?
The proposed sale of 5,000 ORKA common shares is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

What ORKA share sales has Laura Sandler made in the past three months?
The filing reports that Laura Sandler sold 5,000 ORKA common shares on 07/01/2026 for $472,078.50 and 600 shares on 06/15/2026 for $41,814.00 under the three‑month sales history section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR